Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets OK to Market Molecular Dx Tests in Canada, Mexico

NEW YORK (GenomeWeb News) – Cepheid said today that regulatory authorities in Canada and Mexico have cleared for marketing certain of the firm’s molecular diagnostic tests for hospital-acquired infections.
The Sunnyvale, Calif.-based firm said that Health Canada had issued a medical device license for its Xpert GBS, which detects Group B Streptococcus, and Xpert EV for detection of enterovirus-associated meningitis. It said that Fisher Scientific, a division of Thermo Fisher Scientific, will exclusively distribute the tests in Canada.
Cepheid received marketing clearance earlier this year from Health Canada for its Xpert MRSA test for detection of methicillin-resistant Staphylococcus aureus.
All of the tests run on the firm’s GeneXpert System, an automated molecular diagnostic instrument system that combines on-board sample preparation with PCR amplification.
Cepheid also said that regulatory authorities in Mexico had registered the firm’s GeneXpert System, as well as the MRSA, GBS, and EV tests. Those products will be exclusively distributed in Mexico by IL Diagnostics.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.